With H2 typically stronger than H1, Piramal Pharma's management said it is well-positioned to deliver a strong FY performance, supported by healthy order book and encouraging customer engagement.
With H2 typically stronger than H1, Piramal Pharma's management said it is well-positioned to deliver a strong FY performance, supported by healthy order book and encouraging customer engagement.
<iframe src="https://hindustansphere.com/embed/cluster/ec5e8c4591efb5e8b92d464eecec6b66eb2390ba" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Piramal Pharma soars 15% in weak market on huge volume post Q2 results"></iframe>
